
Cipla CIPL.NS drops ~2% to 1,514.30 rupees; had lost 2.6% in last session
On analyst call, India's no. 3 drugmaker lowers FY26 EBITDA margin outlook, citing declining contribution from generic Revlimid, higher R&D costs
CLSA sees tepid H2 for co, almost negligible contribution from gRevlimid
On Thursday, Cipla beat Q2 profit view, announced CEO rejig
Stock rated "buy" on avg; median PT is 1,720 rupees, per data compiled by LSEG
YTD, CIPL gains 0.9%